CD20XCD3 Bispecific Antibody
May 13, 2024
Bispecific and Trispecific Antibodies: Are They Better Than CAR-Ts?
CAR-T therapy has been given the green light for treating blood cancers, but it hasn’t demonstrated sustained effectiveness against solid tumors thus far. The focus of ongoing CAR-T development leans heavily toward blood cancers rather than solid ones. On the other hand, bispecific antibodies have gained approval f...
Read More...
May 23, 2023
Abbvie-Genmab’s EPKINLY Approval for DLBCL Treatment: The First CD20XCD3 Bispecific Antibody
Abbvie-Genmab’s EPKINLY, the first CD20XCD3 Bispecific Antibody gets US approval for Relapsed/Refractory DLBCL treatment. Roche’s Glofitamab is expected to garner benefits in Europe first. Let's have a glimpse of evolving DLBCL treatment landscape in Relapsed/Refractory setting and if bi-specific as a class can be...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
